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The International Federation of Gynaecology and Obstetrics (FIGO) score identifies 
gestational trophoblastic neoplasia (GTN) patients as low- or high-risk of single-agent 
chemotherapy resistance (SACR). Computed tomography (CT) has greater sensitivity 




589 patients underwent both CXR and CT during GTN assessment. Treatment 
decisions were CXR-based. Number of metastases, risk scores and risk-category 
using CXR versus CT were compared. CT-derived chest assessment was evaluated 
as impact upon treatment-decision compared to patient outcome, incidence of SACR, 
time-to-normal-hCG (TNhCG) and primary chemotherapy resistance (PCR).  
 
Results 
Metastasis detection (p<0.0001) and FIGO score (p=0.001) were higher using CT 
versus CXR. CT would have increased FIGO score in 188 (31.9%), with 43 re-
classified from low- to high-risk, of whom 23 (53.5%) received curative single-agent 
chemotherapy. SACR was higher when score (p=0.044) or risk-group (p<0.0001) 
changed. Metastases on CXR (p=0.019) but not CT (p=0.088) lengthened TNhCG. 
Logistic regression analysis found no difference between CXR (AUC=0.63) versus CT 







CT chest would improve the prediction of SACR, but does not influence overall 
treatment outcome, TNhCG or prediction of PCR. Lower radiation doses and cost 








Gestational trophoblastic neoplasia (GTN) is generally classified using the 
International Federation of Gynecology and Obstetrics (FIGO) scoring system, 
identifying patients at low- (score ≤6) or high-risk (score ≥7) of resistance to single -
agent chemotherapy.1 The system can be applied to patients diagnosed with GTN 
after a complete or partial hydatidiform mole, invasive mole or choriocarcinoma, but 
cannot be used for the rarer tumour subtypes of Placental-site- (PSTT) or Epithelioid 
-trophoblastic tumour (ETT) due to their differing behaviour and characteristics.2-6 In 
the United Kingdom (U.K), women with low-risk GTN receive single-agent 
Methotrexate whilst high-risk patients receive multi-agent chemotherapy, usually 
EMA-CO (Etoposide, Methotrexate, Actinomycin D/ Cyclophosphamide and 
Vincristine).5  
 
The FIGO scoring system uses chest X-ray (CXR) as standard to assess pulmonary 
metastases. In UK practice, pulmonary metastases are evaluated on CXR, with 
computed tomography (CT) only performed if there is an uncertainty over the presence 
of lesions on CXR.5 As previously acknowledged by the FIGO committee,7,8 CT chest 
offers advantages over CXR in terms of increased detection of pulmonary metastases, 
yet the impact upon treatment decisions and outcome is unknown, leading to 
longstanding controversy regarding its routine use in the assessment of GTN.7,9-14 One 
issue concerns whether pulmonary metastases detectable only on CT are of clinical 
importance, with some studies concluding that they are a significant prognostic factor 
for single-agent chemotherapy resistance and longer time to achieve first normal 
human chorionic gonadotrophin hormone (TNhCG),7,11,15 whilst others 





(low-risk only, low- and high-risk patients), with varying outcome measures, such as 
chemotherapy resistance, time to remission or disease recurrence. In several previous 
studies, a separate analysis of patients with metastases detectable only on CT has 
not been performed, making conclusions difficult to deduce.7,9,13,15,16  Given the rare 
nature of GTN, and the use of incomplete, retrospective datasets, accurate statistical 
comparisons are problematic.7,9,16 
 
To resolve the controversy regarding the role of CT chest in the assessment of GTN, 
we examined a large UK dataset of patients from a leading Gestational Trophoblastic 
Disease Centre. CT derived chest assessment was evaluated in four different ways: 
(i) the effect upon treatment decisions compared to actual patient outcome; (ii) 
observed incidence of single-agent chemotherapy resistance; (iii) the effect upon 
TNhCG; a surrogate marker for remission;7 and (iv) the prediction of primary 
chemotherapy resistance in all treated patients. Separate secondary analyses were 
performed; (1) upon groups (i)-(iii) to study patients with chest metastases detectable 
only on CT; and (2) to analyse the incidence of relapse and death in the dataset. 
Treatment decisions were based upon CXR derived assessment of GTN, and 




All patients diagnosed with GTN and referred to the Sheffield Trophoblastic Centre 
between January 1973 and April 2019 (n=1294) were included in this study. Patients 
were excluded if they had: (i) histology inconsistent with Gestational Trophoblastic 





Centre; (ii) were not treated (with either chemotherapy or surgery beyond the initial 
uterine evacuations); (iii) diagnosed with rare histological subtypes of PSTT or ETT; 
and (iv) duplicate data entries. Included patients had: (i) undergone both a CXR and 
CT chest during initial investigations for GTN; (ii) a complete FIGO score, including a 
breakdown of the eight contributing components; and (iii) outcome data regarding 
single-agent and primary chemotherapy response (treatment resistance (TR) versus 
complete response (CR)). Single-agent chemotherapy involved patients categorised 
as low-risk, whereas primary chemotherapy was defined as first-line treatment in low- 
or high-risk patients, and as such could be single- or multi-agent.  TR to single-agent 
or primary chemotherapy was defined as a rise in ≥2 serial serum human chorionic 
gonadotrophin (hCG) levels over four weeks, or ≥3 consecutive hCG readings that did 
not fall as expected (by approximately 25%) over the same time period 17.  Relapse 
was defined as ≥2 rising serial serum hCG levels in the absence of a new pregnancy 
or alternative explanation, following ≥6 weeks of normal serum hCG levels following 
the completion of chemotherapy to initially achieve CR.18  Treatment decisions were 
entirely based upon CXR derived assessment of GTN. Selection and details of 
chemotherapy regimens can be found in Supplementary Table S1. 
 
CXR and CT chest images were reviewed and re-reported when the original report did 
not comment upon the exact number and size of metastases. In line with the criteria 
previously reported by Price et al.,9 radiographic features deemed to represent 
metastases included solid, well-defined lesions of a round shape in the proximity of, 
or at the end of a vessel, with evidence of surrounding haemorrhage (ground-glass 
opacification). Multiple small lesions were assumed to be metastases, whilst lesions 





lesion (oval in shape, thickened interlobular septa) were excluded. Lesions that 
remained uncertain in nature were reviewed upon serial imaging, and those that did 
not resolve with treatment were deemed to be non-metastatic and excluded from the 
analysis. Lesions of all sizes that satisfied the above criteria were included and 
counted, to the smallest detectable size of 1mm.   
 
Statistical analysis  
Raw data (total number of metastases, FIGO score and TNhCG) were checked for 
normality (Shapiro-Wilk test) prior to statistical analysis. Wilcoxon matched-pairs 
signed rank test was used to compare the total number of metastases detected on 
CXR versus CT. Paired nominal data in terms of FIGO risk category (low-risk versus 
high-risk) and response to single-agent chemotherapy (TR versus CR) were 
compared using McNemar’s test. Fisher’s exact test was used to compare rates of 
single-agent chemotherapy resistance amongst patients whose total FIGO score and 
risk-category had changed as a result of CT derived chest imaging. Differences in 
TNhCG were investigated using the log-rank Mantel-Cox test. Finally, binomial logistic 
regression analyses were used for the prediction of TR to primary chemotherapy using 
multiple categorical or continuous variables, with no assumption of independence 
between these variables. Statistical analyses were performed in GraphPad Prism 







Of the 1294 patients included, 589 met the inclusion criteria (CONSORT diagram and 
Supplementary Table S2). The total number of metastases detected on CT chest was 
significantly higher than on CXR (Wilcoxon matched-pairs signed rank test p<0.0001, 
CT interquartile range (IQR)=3, CXR IQR=1). Therefore, the FIGO score derived using 
CT was significantly higher compared to CXR (Mann Whitney test p=0.001) (Figure 1 
and Supplementary Figure S1). Using CT, the FIGO score would have been different 
in 195 (33.1%) cases, increasing in 188 patients (96.4%) by a median of 1 point (IQR 
1-3, maximum 4 points) and decreasing in 7 patients (3.6%) by a median of 1 point 
(IQR 1-2, maximum 2 points). This would have affected the categorisation of patients 
into low- or high-risk groups (McNemar’s test, p<0.001) (Table 1); with CT reclassifying 
43 (7.3%) patients from the low- to high-risk group. 
 
Impact upon treatment decisions and patient outcome 
All treatment decisions were based upon CXR alone.  However, if CT had been used, 
of the 43 patients who would have been reclassified from the low- to high-risk group, 
14 (32.6%) had CR, and 29 (67.4%) demonstrated TR to single-agent chemotherapy 
(Fig. 2). All received Methotrexate based upon their original score. 
 
Of the 29 patients who had TR to single-agent chemotherapy, 9 were cured with 
second-line single-agent chemotherapy (Dactinomycin n=8, Carboplatin n=1). 
Therefore, despite being changed from the low- to high-risk group, 23 (53.5%) of the 






The remaining 20 patients with TR to single-agent chemotherapy required multi-agent 
second- (n=15) or third-line (n=5) chemotherapy or surgery (total abdominal 
hysterectomy) to achieve a cure (Figure 2). 
 
Observed incidence of single-agent chemotherapy resistance 
The incidence of TR to single-agent chemotherapy was significantly higher amongst 
patients whose FIGO score would have changed using CT versus those whose score 
remained unchanged (Fisher’s exact test p=0.044) (Table 2). The incidence of TR to 
single-agent chemotherapy was also statistically higher in patients who would have 
changed from low- to high-risk groups, versus those whose risk did not change 
(Fisher’s exact test p<0.0001) (Table 3). 
 
Effect upon time to remission (TNhCG) 
Patients with pulmonary metastases identified on CXR had a significantly longer 
TNhCG: median TNhCG with no metastases on CXR = 174 days versus 201 days 
with metastases (log-rank Mantel-Cox test p=0.014). However, metastases on CT 
were not associated with a longer TNhCG: median TNhCG with no metastases on CT 
= 173 days versus 182 days with metastases (log-rank Mantel-Cox test p=0.088). 
TNhCG did not differ between patients who would have changed risk category 
compared to those whose risk remained unchanged: median TNhCG 181 versus 175 
days respectively (log-rank Mantel-Cox test p=0.875). 
 
Referring to the larger patient dataset of 1041 patients diagnosed with GTN who 
required treatment (chemotherapy or surgery other than uterine evacuations), simply 





patients who had a CT chest versus 169 days in 360 patients who did not undergo a 
CT chest) (log-rank Mantel-Cox test p=0.063).  
 
Pulmonary metastases detectable only on CT  
In 145 (24.6%) patients, pulmonary metastases were detectable only on CT, which 
was associated with a statistically higher FIGO score compared to patients with a clear 
CXR (median of 5 versus 4, Mann Whitney test p<0.0001) or clear CT (median of 5 
versus 3, Mann Whitney test p<0.0001). The FIGO score increased in all 145 patients 
by a median of 1 point, which would have led to 36 (24.8%) patients being re-classified 
from the low- to high-risk group.  The incidence of TR to single-agent chemotherapy 
would have been significantly higher amongst patients who changed from low- to high-
risk groups, compared to those whose risk remained unchanged (Fisher’s exact test 
p=0.0007). 
 
Of the 36 patients who would have changed from low- to high-risk groups, 13 (36.1%) 
experienced CR to single-agent chemotherapy.  The remaining 23 (63.9%) patients 
had TR, of whom 5 were subsequently cured with second-line single-agent 
chemotherapy (dactinomycin).  Overall, 18 (50%) patients were cured with first- or 
second-line single-agent chemotherapy.  The remainder required multi-agent 
chemotherapy or surgery as second- (n=14) or third-line (n=4) management. 
 
The incidence of TR to single-agent chemotherapy did not differ between patients with 







Patients with pulmonary metastases detectable only on CT did not have a longer 
TNhCG compared to those with a clear CT chest: median TNhCG 177 days versus 
173 days respectively (log-rank Mantel-Cox test p=0.440). 
 
Prediction of primary chemotherapy resistance  
The influence of CXR versus CT derived FIGO score on the prediction of TR to primary 
chemotherapy was compared using binomial logistic regression analyses. As a 
baseline, the capacity of the FIGO score (derived using standard CXR based chest 
imaging) to predict TR to primary chemotherapy was poor, with an area under the 
curve (AUC) of 0.61. For a FIGO score of 7 (the cut-off score for categorising patients 
as low- versus high-risk), the model had a sensitivity of 0.12 and specificity of 0.88. 
(Figure 3A). 
 
Further analyses were conducted using the categorised data from the eight clinical 
risk factors that constitute the FIGO score. Comparing the predictive models derived 
from them using either CXR (Figure 3B) or CT (Figure 3C) based chest imaging, 
revealed a slight, but non-significant improvement to the AUC (AUC=0.63 versus 0.64 
respectively). Despite the small change to the overall AUC, the shape of the ROC 
curves for both datasets were superior to the baseline curve, particularly in the low 
false positive/sensitivity range. This is reflected in the superior sensitivity values when 
matching the specificity achieved by a FIGO score of 7, with a sensitivity of 0.27 using 
CXR data (Figure 3B) versus 0.31 using CT data (Figure 3C). In summary, combining 
the categorised scores from the eight clinical risk factors in a logistic regression model, 





(CXR based chest assessment) or 19 patients (CT based chest assessment) who 
would have TR to primary chemotherapy.  
 
Investigating the eight FIGO risk factors more closely, only two were predictive of 
primary chemotherapy resistance. Within both CXR and CT chest derived logistic 
models, the most significant factor was hCG score (p<0.001), with antecedent 
pregnancy next (p<0.05 for CT and p<0.06 for CXR models) (Figure 3B and 3C). 
 
Incidence of relapse and death 
Median follow up from date of evacuation was 51.7 months (IQR=18.0-70.2 months). 
A total of 18 patients relapsed. The incidence of relapse was unaffected by the 
presence of pulmonary metastases detected on CXR (Fisher’s exact test p=0.189, 
n=589) or CT chest (Fisher’s exact test p=0.224, n=589) (Supplementary Table S3). 3 
patients died from Gestational Trophoblastic Neoplasia.  Of these, 1 patient had 
pulmonary metastases detected on CXR, whilst 2 patients had metastases on CT 
chest.   
 
Discussion 
The use of CT chest over CXR in the assessment of GTN is historically controversial. 
CT would detect more chest metastases compared to CXR; increasing the FIGO score 
and changing the risk category in a proportion of patients. CT would have improved 
the prediction of patients who were resistant to single-agent chemotherapy, but 
crucially would not have improved the outcome for these patients. Overall the use of 
CT would not improve the prediction of primary chemotherapy resistance in the whole 





CT were not associated with a longer TNhCG, unlike metastases detected on CXR.  
Equally, the incidence of relapse was unaffected by the presence of metastases on 
CXR or CT. 
 
Using CT chest, 7.3% patients would have changed from low- to high risk, with  a 
statistically higher rate of TR to single-agent chemotherapy, compared to patients 
whose risk did not change, in agreement with the findings of Price et al.9 but dissimilar 
to an earlier study by Darby et al..7 This may be explained by the smaller patient 
numbers in the latter study. In our study, a significant proportion (53.5%) of the patients 
who changed risk category would have been over-treated and unnecessarily 
subjected to the more potential extensive physical, psychological and longer-term side 
effects associated with high-risk chemotherapy regimens such as EMA-CO.17,19 These 
figures are in agreement with previous literature comparing CT versus CXR derived 
FIGO scores, whereby 8.3-10.4% patients changed risk category and 50-55% of these 
responded to single-agent chemotherapy.7,9 Given the young patient population 
affected by GTN, and the frequent desire for further pregnancies, avoiding 
overtreatment is essential, as is the need to minimise the radiation dose. Despite 
technological advancements, CT chest delivers 7 millisieverts (mSv) of radiation, 
equivalent to ~1065 days of natural background radiation exposure.  The radiation 
dose is 350 times higher than a standard postero-anterior CXR which delivers 
0.02mSv radiation, equivalent to 3 days of background radiation.20 Even low-dose CT 
used for lung cancer screening delivers ~1.4mSv radiation; 70 times higher than 
CXR.21 Pregnant breast tissue is highly susceptible to radiation,22 which applies to 
GTN patients (all of whom have a raised hCG level), with an increased long-term risk 





pulmonary assessment must also be considered, particularly in lower-income 
countries, where the prevalence of GTN is higher compared to the UK.24 Access to 
and the increased cost of CT compared to CXR could prevent consistent and 
comparable investigation of GTN patients across the world. 
 
Metastases detected on CXR, were found to be associated with an extended  TNhCG, 
supporting the literature in low-risk patients, suggesting that pulmonary metastases 
present at the start of treatment are associated with higher rates of TR 7,13,15,18 and 
disease recurrence.16,18 Metastases detected on CT were not associated with a longer 
TNhCG. 
 
In the secondary, separate analysis of patients with pulmonary metastases detectable 
only on CT chest, 24.8% would have changed from the low- to high-risk category, and 
had a statistically higher rate of TR to single-agent chemotherapy compared to those 
who did not change risk group. However similar to patients with pulmonary metastases 
detectable on both CXR and CT, 50% had a CR to single-agent first- or second-line 
chemotherapy and would have been over-treated using CT derived assessment. 
Crucially TR to single-agent chemotherapy or TNhCG would not have differed 
between patients with metastases detectable only on CT compared to those with a 
clear CT, in agreement with previous literature,10,14 but in disagreement with one of 
the earliest studies by Mutch et al..11 The discrepancy with our findings is likely to be 
explained by the demonstrably larger patient population included within our study, and 
the improving resolution of modern CT imaging, which can more accurately classify 
small benign versus malignant chest lesions. Several previous studies included 





metastatic versus non-metastatic disease, hence it is impossible to deduce accurate 
conclusions regarding their true prognostic significance.7,9,13,15,16 
 
Additional secondary analyses revealed that the incidence of relapse was unaffected 
by pulmonary metastases detected on CXR and CT. A similar analysis could not be 
performed upon the incidence of death due to the small numbers within the dataset 
(n=3).  Unfortunately, previously published literature comparing CXR and CT did not 
study these outcome measures.7,9,13 Frijstein et al.18 demonstrated higher rates of 
disease recurrence amongst low-risk patients with pulmonary metastases, compared 
to those without pulmonary metastases. However, as our study included both low- and 
high-risk patients, the two studies cannot be compared. Similarly, other literature 
showing higher rates of relapse amongst patients with lung metastases16 only 
analysed those with single site (lung) metastases and excluded patients with 
metastases at other sites. Our study included patients with both pulmonary and extra-
pulmonary metastases at initial assessment.  
 
With regard to multivariate analysis of all FIGO 2000 scoring variables using either 
CXR or CT, hCG level and antecedent pregnancy were the most important factors for 
predicting primary-treatment resistance, confirming that the use of CT chest did not 
confer a major prognostic benefit. This conflicts with previously published literature, 
indicating that metastases on CT chest were the most significant predictor for TR on 
both uni- and multivariate analysis.13 However, that study analysed only six of the eight 
risk factors within the FIGO system and involved a much smaller patient cohort 






This study incorporates a large dataset from one of the leading Trophoblastic Centres 
within the UK.  Limitations of this study include the retrospective analysis, changes 
and advances in CT imaging (protocols, slice thickness, resolution) during the time 
period under study; potentially allowing the detection of smaller pulmonary metastases 
and improved differentiation of metastatic compared to non-metastatic lesions on 
more contemporaneous images. One approach would have been to analyse only 
images taken over the last decade; however this would have dramatically reduced the 
sample size and power of the study.  Previous studies25 have raised concerns that 
small pulmonary lesions detectable on modern-day CT imaging may in fact represent 
trophoblastic emboli seen even in healthy pregnancies, rather than metastatic GTN, 
again leading to over-treatment and the un-necessary exposure of patients to more 
toxic chemotherapy regimens.  However, it is impossible to differentiate between such 
lesions as both resolve over time with or without chemotherapy, while it would be 
harmful to expose patients to repeated CT chest imaging to monitor the change of 
such lesions.  
 
Weighing the pros- and cons of CT versus CXR derived pulmonary imaging in the 
assessment of GTN, this study does not support the use of CT. CXR should remain 
the recommended modality of choice for imaging pulmonary metastases as part of 
FIGO score. The higher radiation dose; increased cost; lack of influence on outcome 
or prognostic measures render the routine introduction of CT chest in the assessment 
of GTN patients unnecessary. Furthermore, this study raises questions concerning 
whether CT chest should be performed even in the instance of an indeterminate CXR, 
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Manuscript Figures and legends 
 
Figure 1. Box and whisker plot comparing the FIGO scores calculated using CXR 
versus CT based imaging of pulmonary metastases. The threshold line 
delineates a FIGO score of 7; the cut-off for categorising patients as low- versus 
high-risk.  
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; CXR, 







Figure 2. Flow diagram of the treatment outcomes for the 43 patients who 
changed from low- to high-risk using CT based pulmonary imaging. All patients 
ultimately had a CR and survived.  
Abbreviations: CT, computerised tomography (chest); TR, resistance to single-agent 









Figure 3. Logistic regression analysis. A: Using only FIGO score (at a score of 
7, sensitivity=0.12, specificity=0.88); B: Using the categorised scores from the 
eight clinical risk factors that constitute the FIGO score, including data derived 
from CXR chest staging. Matching the specificity achieved by the FIGO score of 
7 (0.88), sensitivity is raised to 0.27; C: Using the categorised scores from the 
eight clinical risk factors that constitute the FIGO score, including data derived 
from CT chest staging. Matching the specificity achieved by the FIGO score of 
7 (0.88), sensitivity is raised to 0.31. 
Abbreviations: CXR, chest X-ray; CT, computerised tomography (chest); AUC, area 







Manuscript Tables and legends 
Table 1. Number of low- and high-risk patients predicted using CXR versus CT 
chest derivation of the FIGO score, (McNemar’s test p<0.001, n=589). 
Abbreviations: CXR, chest X-ray; CT, computerised tomography (chest), LR; low-risk 
of single-agent chemotherapy resistance; HR; high-risk of single-agent chemotherapy 
resistance. 
   CT  
    LR HR 
CXR 
LR 475 43 






Table 2: Using CT chest, the breakdown of single-agent chemotherapy 
response of patients whose FIGO score changed (n=195) versus those whose 
score remained unchanged (n=394), (Fisher’s exact test p=0.0435, n=589).  
Abbreviations: CXR, chest X-ray; CT, computerised tomography (chest); TR, 
resistance to single-agent chemotherapy; CR, complete response to single-agent 
chemotherapy. 
 
  Response to single-agent treatment (% of total) 
  TR CR 
Score unchanged with CT  126 (32.0) 268 (68.0) 











Table 3: Using CT chest, breakdown of single-agent chemotherapy response of 
patients whose FIGO category changed from low- to high-risk (n=43) versus 
those whose risk category remained unchanged (n=546), (Fisher’s exact test 
p<0.0001, n=589). 
Abbreviations: CXR, chest X-ray; CT, computerised tomography (chest); TR, 




Response to single-agent treatment (% of total) 
 
TR CR 
Risk category unchanged with CT  176 (32.2) 370 (67.8) 






















Figure S1. Histogram comparing of the FIGO scores calculated using CXR 
versus CT chest. The green threshold line delineates a FIGO score of 7; the cut-
off for categorising patients as low- versus high-risk of single-agent 
chemotherapy resistance.  
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; CXR, 







Table S1. Low- and high-risk treatment regimens at The Sheffield Trophoblastic Centre 
Abbreviations: hCG, human chorionic gonadotrophin, IU/L, international units per litre. 
Treatment  Regimen description 
Low-risk 1st line 
Methotrexate (MTX): 50mg given intramuscularly every 48 hours for 4 doses, with oral folinic acid given 30 
hours after MTX, i.e. MTX on days 1,3,5,7 and folinic acid on days 2,4,6,8.  Course repeated every 2 weeks. 
Low-risk 2nd line (hCG <300 IU/L or hCG >300 but <3000 IU/L) Actinomycin D: intravenous bolus at a dose of 1.25mg/m2 repeated every two weeks. 
Low-risk 2nd line (hCG >3000 and <30,000 IU/L) Carboplatin (AUC4) intravenous repeated every 2 weeks. 
Low-risk 2nd line (hCG >30,000 IU/L) 
EA (Etoposide/Actinomycin D): E:100 mg/m2 given intravenous, days 1–3, A:0.5 mg intravenous, days 1–3, 
involving a two night hospital stay, every 10-days.  
Low-risk 3rd line (after MTX and Carboplatin) 
EA (Etoposide/Actinomycin D): E:100 mg/m2 given intravenous, days 1–3, A:0.5 mg intravenous, days 1–3, 
involving a two night hospital stay, every 10-days.  
High-risk  
EMA/CO: EMA: Day 1 [Actinomycin: 0.5mg intravenous bolus followed by Etoposide 100mg/m2 in 500mL 
normal saline as a 1 hour infusion, followed by MTX 300mg/m2 intravenous over 12 hours in 1L normal 
saline], Day 2 [Actinomycin D 0.5mg given as an intravenous bolus followed by Etoposide 100mg/m2 in 
500mL normal saline as a 1 hour infusion, folinic acid 15mg 6 hourly, given intravenous or orally, 24 hours 
after the start of MTX. Eight doses are administered]. CO: Day 8 [Vincristine 0.8mg/m2 given intravenous in 
50mL normal saline over 10 minutes, followed by Cyclophosphamide 600mg/m2 given intravenous in 250mL 










Abbreviations: IQR, Interquartile range, data presented as 25th and 75th percentile; mm, millimetres; IU/L, international units per 
litre; hCG, human chorionic gonadotrophin; FIGO, International Federation of Gynecology and Obstetrics; CXR, chest X-ray; CT, 
computerised tomography (chest). 










Time to normal 


















4.21 2791 to 59,481 1 to 3  143 to 227 12 to 60 0 to 1 2 to 5 15 to 60 0 to 3 2 to 6 
Minimum 14.68 0.18 7 1 59 0 0 0 0 0 0 
Maximum 56.62 135.80 1,454,810 4 6475 150 19 21 150 70 21 






Table S3. Incidence of relapse (n=18) in patients with pulmonary metastases 
detected on CXR (Fisher’s exact test p=0.189, n=589) or CT chest (Fisher’s 
exact test p=0.224, n=589). 
Abbreviations: CXR, chest X-ray; CT, computerised tomography (chest). 
  Relapse No relapse  Relapse No relapse 
Pulmonary metastases detected 
on CXR 
5 90 
Pulmonary metastases detected 
on CT 
10 228 
No pulmonary metastases 
detected on CXR 
13 481 
No pulmonary metastases 
detected on CT 
8 343 
 
 
